Comparison of cytopathologic findings in patients with negative Pap test and positive high-risk HPV infection among three groups
- 1 March 2022
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 306 (3) , 857-863
Abstract
Purpose Comparison of colposcopy-guided biopsy and endocervical cytologic (ECC) results in patients with negative Papanicolaou (Pap) and positive high-risk (HR) HPV tests in the three groups of HPV 16/18, non-16/18 HR-HPV (other HR-HPV), and concurrent infection of either HPV 16/18 and at least one subtype of other HR-HPVs. Methods This cross-sectional study was conducted among women aged 30–65 who had negative Pap and positive HR-HPV DNA tests. Pap test was performed using liquid cytology. For HPV DNA testing, the polymerase chain reaction (PCR) method was used. Results Among 394 participants, 111 (28.2%) were in the HPV 16/18, 226 (57.4%) in the Other HR-HPV, and 57 (14.4%) in the concurrent group. The mean age of participants was 35.71 ± 7.1 years. Cervical intraepithelial neoplasia (CIN) grade 2/3 were seen in 29 (26.1%) patients of HPV 16/18, 60 (26.5%) of other HR-HPV, and 18 (31.6%) of concurrent infection group (P = 0.593). HPV 52 was the most common subtype in the other HR-HPV group (15%). Conclusions The risk of high-grade CIN lesions in patients with negative Pap test and positive other HR-HPV was not significantly less than patients with positive HPV 16/18. Besides, the risk of losing the patients to 1-year follow-up seems high.Keywords
This publication has 25 references indexed in Scilit:
- The Pap test and Bethesda 2014Cancer Cytopathology, 2015
- Screening Behaviors and Cultural Barriers in Women with Newly Diagnosed Cervical CancerJournal of Lower Genital Tract Disease, 2013
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage LevelsJNCI: Journal of the National Cancer Institute, 2013
- Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical CancerVaccine, 2012
- Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology-Negative ResultsAmerican Journal of Clinical Pathology, 2011
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA studyThe Lancet Oncology, 2011
- Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening TestJNCI: Journal of the National Cancer Institute, 2008
- Human papillomavirus and cervical cancerThe Lancet, 2007
- Association between Quantitative High-Risk Human Papillomavirus DNA Load and Cervical Intraepithelial Neoplasm RiskCancer Epidemiology, Biomarkers & Prevention, 2005
- Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up studyBMJ, 2002